Previous Close | 1.1700 |
Open | 1.1600 |
Bid | 1.2500 x 1800 |
Ask | 1.3000 x 3100 |
Day's Range | 1.1350 - 1.2000 |
52 Week Range | 0.5900 - 11.1200 |
Volume | |
Avg. Volume | 1,973,208 |
Market Cap | 81.564M |
Beta (5Y Monthly) | 0.22 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2700 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for ACRS
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Aclaris Therapeutics ( NASDAQ:ACRS ) Full Year 2023 Results Key Financial Results Revenue: US$31.2m (up 5.0% from FY...